InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Explore the full record of transactions filed by Maag Peter, Board Member and former Executive Chairman of CareDx, Inc.. Insider active across 2 companies, notably CareDx, Inc.. Aggregated, 47 reports have been published. Total volume traded: €791k. The latest transaction was filed on 16 June 2022 — Attribution. Regulator: SEC (Form 4). All data is free.
Declarations47 total
04,863 shares0
Common Stock
SEC:0001217234-22-000113:0·
€35,0713,125 shares@ €11.22270.0034% mcap0.5% of flow
Common Stock
SEC:0001217234-22-000078:0·
€18,9431,683 shares@ €11.25570.0018% mcap0.3% of flow
Common Stock
SEC:0001217234-22-000062:0·
€178,8034,900 shares@ €36.49030.017% mcap5.9% of flow
Common Stock
SEC:0001217234-22-000042·
€178,8034,900 shares@ €36.49030.017% mcap2.7% of flow
Common Stock
SEC:0001217234-22-000042:0·
€40,1511,132 shares@ €35.46920.0039% mcap0.6% of flow
Common Stock
SEC:0001217234-22-000036:0·
€40,1511,132 shares@ €35.46920.0039% mcap1.3% of flow
Common Stock
SEC:0001217234-22-000036·
€440,1265,702 shares@ €77.1880.043% mcap6.8% of flow
Common Stock
SEC:0001217234-22-000027:0·
€440,1265,702 shares@ €77.1880.043% mcap14.6% of flow
Common Stock
SEC:0001217234-22-000027·
€5,173925 shares@ €5.59220.0005% mcap0.2% of flow
Common Stock
SEC:0001217234-22-000012·
€5,173925 shares@ €5.59220.0005% mcap0.1% of flow
Common Stock
SEC:0001217234-22-000012:0·
€5,169926 shares@ €5.58170.0005% mcap0.2% of flow
Common Stock
SEC:0001217234-21-000253·
€5,169926 shares@ €5.58170.0005% mcap0.1% of flow
Common Stock
SEC:0001217234-21-000253:0·
€5,051925 shares@ €5.46070.0005% mcap0.2% of flow
Common Stock
SEC:0001217234-21-000242·
€5,051925 shares@ €5.46070.0005% mcap0.1% of flow
Common Stock
SEC:0001217234-21-000242:0·
€5,039926 shares@ €5.44150.0005% mcap0.2% of flow
Common Stock
SEC:0001217234-21-000225·
€5,039926 shares@ €5.44150.0005% mcap0.1% of flow
Common Stock
SEC:0001217234-21-000225:0·
€4,928925 shares@ €5.32780.0005% mcap0.2% of flow
Common Stock
SEC:0001217234-21-000210·
€4,928925 shares@ €5.32780.0005% mcap0.1% of flow
Common Stock
SEC:0001217234-21-000210:0·
€427,0006,198 shares@ €68.89310.041% mcap14.2% of flow
Common Stock
SEC:0001217234-21-000200·
€427,0006,198 shares@ €68.89310.041% mcap6.5% of flow
Common Stock
SEC:0001217234-21-000200:0·
€216,6273,096 shares@ €69.96990.021% mcap7.2% of flow
Common Stock
SEC:0001217234-21-000196·
€216,6273,096 shares@ €69.96990.021% mcap3.3% of flow
Common Stock
SEC:0001217234-21-000196:0·
€23,9322,312 shares@ €10.35140.0023% mcap0.8% of flow
Common Stock
SEC:0001217234-21-000171·
€23,9322,312 shares@ €10.35140.0023% mcap0.4% of flow
Common Stock
SEC:0001217234-21-000171:0·
25 of 47 declarations
About Maag Peter
Peter Maag is an experienced life sciences and healthcare executive with a strong background in corporate leadership and board governance across U.S.-listed companies. He has served on the Board of Directors of CareDx, Inc. since November 2012 and became Executive Chairman of the Board in November 2020, after having served as Chairman and Chief Executive Officer. CareDx states that he joined the company in 2012 as Chief Executive Officer and guided it through its IPO and a period of strategic development and transformation. ([investors.caredx.com](https://investors.caredx.com/files/doc_news/Peter-Maag-Appointed-Executive-Chairman-of-the-Board-of-Directors-of-CareDx-Reginald-Seeto-Appointed-President-and-CEO-10-29-2020-2020.pdf?utm_source=openai)) His earlier career included several senior roles at Novartis International AG, where he held positions of increasing responsibility from 2001 to 2012. CareDx notes that he served as Global Head of Novartis Diagnostics from 2009 to 2012, Country President for Novartis Pharma AG in Germany from 2006 to 2008, Country President for Novartis’ Korea operations from 2003 to 2005, and Head of Strategy for Novartis’ pharmaceutical division from 2001 to 2002. This background reflects substantial expertise in strategy, global business leadership, and diagnostics. ([theorg.com](https://theorg.com/org/miromatrix/org-chart/peter-maag?utm_source=openai)) At CareDx, Maag played a key role in governance and leadership succession, with Reginald Seeto assuming the CEO role in November 2020 while Maag transitioned to Executive Chairman. Company materials also highlight his experience in risk management, strategic oversight, and healthcare transactions. ([investors.caredx.com](https://investors.caredx.com/files/doc_news/Peter-Maag-Appointed-Executive-Chairman-of-the-Board-of-Directors-of-CareDx-Reginald-Seeto-Appointed-President-and-CEO-10-29-2020-2020.pdf?utm_source=openai)) Maag also serves on the Board of Directors of Miromatrix Medical Inc., where he contributes expertise in biotechnology, diagnostics, and corporate governance. Overall, his profile combines operational leadership, international strategy experience, and board-level oversight in innovative healthcare businesses, making him a notable figure in the U.S. public-company ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723422000084/caredxdef14a.htm?utm_source=openai))
